Please enter verification code
Confirm
Histochemical Changes in the Cerebellum of Wistar Rats Administered with Oral Doses of Zidovudine
American Journal of Bioscience and Bioengineering
Volume 3, Issue 3, June 2015, Pages: 17-21
Received: Jul. 30, 2015; Accepted: Aug. 10, 2015; Published: Aug. 19, 2015
Views 4990      Downloads 146
Authors
Aniekan Imo Peter, Department of Anatomy, University of Uyo, Uyo, Nigeria
Gabriel Joseph Ekandem, Department of Anatomy, University of Uyo, Uyo, Nigeria
Anozeng Oyono Igiri, Department of Anatomy, University of Calabar, Uyo, Nigeriap
Moses Bassey Ekong, Department of Anatomy, University of Uyo, Uyo, Nigeria
Dianabasi King Udoh, Chemical Pathology Unit, Med Lab Services, University of Uyo Teaching Hospital, Uyo, Nigeria
Article Tools
Follow on us
Abstract
Zidovudine is a drugs used in the management of Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) infection in sub-Saharan Africa in combination with other drugs. The objective of this research was to investigate the potential harmful effects of this drug on the histology of the cerebellum of Wistar rats. Twenty male Wistar rats were used for this study. The rats were divided into 2 groups of 10 rats each. Group A served as the control and was administered with 1 ml of distill water, while group B was administered with 8.57mg/kg of zidovudine daily for 30 days, after which the rats where sacrificed and each cerebellum was harvested, processed and stained using haematoxylin and Eosin (H/E), silver impregnation method. Paraffin impregnated Glial Fibrilar Acidic Protein (GFAP), Neuron Specific Enolase (NSE) and Neurofilament (NF) immunochemistry methods. Stained slides were viewed using light microscope. Results showed that, the cerebellum of Groups B animals were affected with moderate to severe shrinking and distortion of the Purkinje cells and granular cells, when compared with the control. Group B animals, also showed more expression of GFAP, NSE and NF staining in their cerebellum than the control. This suggests that zidovudine is harmful to the cerebellum and should be taken with caution
Keywords
Zidovudine, Cerebellum, Human Immunodeficiency Virus
To cite this article
Aniekan Imo Peter, Gabriel Joseph Ekandem, Anozeng Oyono Igiri, Moses Bassey Ekong, Dianabasi King Udoh, Histochemical Changes in the Cerebellum of Wistar Rats Administered with Oral Doses of Zidovudine, American Journal of Bioscience and Bioengineering. Vol. 3, No. 3, 2015, pp. 17-21. doi: 10.11648/j.bio.20150303.11
References
[1]
Wright, K. (1986). AIDS Therapy: First Tentative Signs of Therapeutic Promise. Nature, 323 (6086): 283.
[2]
Watts DH. Treating HIV during pregnancy: an update on safety issues. Drug Saf. 2006; 29: 467-490.
[3]
Centers for Disease Control and Prevention (CDC). Update: AIDS among women--United States, 1994. MMWR Morb Mortal Wkly Rep 1995; 44: 81-84.
[4]
Jeffries, D. J. Zidovudine resistant HIV. British Medical Journal (Clinical research ed.) 1989 ; 298 (6681): 1132–1133.
[5]
https://www.pharmgkb.org/pathway/PA165859361 (Retrieved, June1 2015)
[6]
Ghodke,Y., Anderson P. L., Sangkuhl, K., Lamba, J., Altman., R. B. and Klein, T. E. PharmGKB summary: zidovudine pathway. Pharmacogenetics and Genomics 2012; 22:891–894
[7]
Blum, M., Good, S., Liao, S. and de Miranda, P. Pharmacokinetics and Bioavailability of Zidovudine in Humans. American Journal of Medicine, 1989; 85: 189-194.
[8]
Maxwell, S., Scheftner, W., Kessler, H. and Busch, K. Syndrome Associated With Zidovudine Treatment [Letter]. Journal of American Medical Association, 1988; 259: 3406-3407
[9]
Hagler, D. and Frame, P. Azido thymidine neurotoxicity [Letter]. Lancet,1986; 2: 1392-1393.
[10]
http://www.aidsmap.com/resources/treatmentsdirectory/ (Retrieved online on 7/6/14)
[11]
Cronkite, E. P. and Bullis, J. In vivo toxicity of 3′-azido-3′-deoxythymidine (AZT) on CBA/Ca mice. Int. J. Cell Cloning, 1990; 8, 332–345
[12]
Bogliolo, G., Lerza, R., Mencoboni, M., Flego, G., Gasparini, L. and Pannacciulli, I. Hematoxic effects on mice of combined administration of azidothymidine and acyclovir. Exp. Hematol.,1991; 19, 838–841
[13]
Thompson, M. B., Dunnick, J. K., Sutphin, M. E., Giles, H. D., Irwin, R. D. and Prejean, J. D. Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fundam. appl. Toxicol.,1991; 17, 159–176
[14]
Scheding, S., Media, J. E. and Nakeff, A. Acute toxic effects of 3′-azido-3′-deoxythymidine (AZT) on normal and regenerating murine hematopoiesis. Exp. Hematol., 1994; 22, 60–65
[15]
Omar, R. F., Gourde, P., Desormeaux, A., Tremblay, M., Beauchamp, D. and Bergeron, M. G. (1996) In vivo toxicity of foscarnet and zidovudine given alone or in combination. Toxicol. appl. Pharmacol., 139, 324–332
[16]
Inoue, T, Cronkite, E. P., Hirabayashi, Y, Bullis, J. E., Jr, Mitsui, H. and Umemura, T. Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia. Leukemia, 1997; 3, 123–127
[17]
Rao, G. N., Lindamood, C. Heath, J. E., Farnell, D. R, and Giles, H. D. Subchronic toxicity of human immunodeficiency virus and tuberculosis combination therapies in B6C3F1 mice. Toxicol. Sci., 1998; 45, 113–127
[18]
Olivero, O. A., Anderson, L. M., Diwan, B. A., Haines, D. C., Harbaugh, S. W., Moskal, T. J., Jones, A. B., Rice, J. M., Riggs, C. W., Logsdon, D., Yuspa, S. H. and Poirier, M. C. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J. natl Cancer Inst.,1997; 89, 1602–1608
[19]
Bialkowska, A., Bialkowski, K., Gerschenson, M., Diwan, B. A., Jones, A. B. et al. Oxidative DNA damage in fetal tissues after transplacental exposure to 3'-azido-3'-deoxythymidine (AZT). Carcinogenesis.2000; 21: 1059-1062.
[20]
Poirier, M. C., Patterson, T. A., Slikker, W. Jr and Olivero, O. A. Incorporation of 3'-azido-3'-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Immune Defic Syndr. 1999; 22: 477-483.
[21]
http://www.neavs.org/research/biomedical retrieved online on the 6th of August 2015
[22]
Braddy TB, Siegel G J, Albers R.W and Price DL. BasicNeurochemistry Principles of Molecular Medical Neurobiology 8th ed. Wyman USA, Academy press Elservier, 2012;114, 815
[23]
Meng, Q., Fasco, M. J., Bellisario, R., Kaminsky, L., Pass, K. A. et al. Plasma and cellular markers of 3’-azido-3’- deoxythymidine metabolism as indicators of DNA incorporation of 3’-azido-3’-deoxythymidine metabolism as indicators of DNA incorporation of 3’-azido-3’- deoxythymidine in cord blood lymphocytes from infants exposed in utero. Environ Mol Mutagen.2001; 37: 53-58.
[24]
Slamenová, D., Horváthová, E. and, Bartková, M. Nature of DNA lesions induced in human hepatoma cells, human colonic cells and human embryonic lung fibroblasts by the antiretroviral drug 3'-azido-3'-deoxythymidine. Mutat Res.2006; 593: 97-107.
[25]
Chongtham, R., Bhattacharyya, A. and Kumar, M. Histopathological Changes in Multiple Fetal Tissues Exposed In-Utero to Zidovudine Chongtham J AIDS Clin Res 2014, 5:11
[26]
Blanche, S., Tardieu, M., Rustin, P., Slama, A., Barret, B., et al., Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999; 354: 1084-1089.
[27]
De la Asunción, J. G., del Olmo, M. L., Sastre, J., Pallardó, F. V. and Viña, J. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology. 1999; 29: 985-987.
[28]
Ewings, E. L., Gerschenson, M., St Claire, M. C., Nagashima, K., Skopets, B. et al. Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria. J Acquir Immune Defic Syndr. 2000; 24: 100-105.
[29]
Calamandrei, G., Venerosi, A., Branchi, I. and Alleva E. Effects of prenatal zidovudine treatment on learning and memory capacities of preweanling and young adult mice. Neurotoxicology 1999; 20: 17-25
[30]
Venerosi, A., Cirulli, F., Lil'p, I. G., Fiore, M., Calamandrei, G. et al. Prolonged perinatal exposure to AZT affects aggressive behaviour of adult CD-1 mice. Psychopharmacology (Berl) 2000; 150: 404-411.
[31]
Rajlakshmi, C., Trigunayat, A., Bhattacharyya, A. and Pandey BL Neurobehavioural profile of F1 and F2 generation mice following one stage Zidovudine exposure through pregnancy and lactation. Annals of Neurosciences. 2008;15: 69-74.
[32]
Sieh, E., Coluzzi, M. L., Cusella, D., Angelis, M. G., Mezzogiorno, A., Floridia, M. et al. The effects of AZT and DDI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study. AIDS Res Hum Retroviruses. 1992; 8: 639-649.
[33]
Diamond, A. Close interrelation of motor development and cognitive development and of the cerebellum and prefrontal cortex. Child Dev. 2000;71(1):44–56
[34]
Baillieux, H., Smet, H. J., Paquier, P. F., De Deyn, P. P. and Marien P. Cerebellar neurocognition: Insights into the bottom of the brain. Clin Neurol Neurosurg. 2008;110(8):763–73.
[35]
Ito M. Movement and thought: identical control mechanisms by the cerebellum. Trends Neurosci. 1993;16(11):448–50
[36]
Fiez, J. A. Cerebellar contributions to cognition, Neuron, 1996; 16: 1, pp. 12– 15,
[37]
Chizhikov, V. and. Millen, K. J. Development and malformations of the cerebellum in mice, Molecular Genetics and Metabolism, 2003; 80 (1-2) 54–65,
[38]
Kiernan, J. (2009) The Human Nervous System. Ontario, Canada: Lippincott William and Wilkins. Chapter18, Page 267- 274.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186